C&EN, September 26, 2020
Hovione has signed an agreement to significantly ramp up output of Ligand Pharmaceuticals’ Captisol, a chemically modified cyclodextrin that improves drugs’ solubility and stability. Gilead Sciences uses the excipient to formulate the COVID-19 treatment remdesivir. “Hovione will soon be producing per month the quantity it usually produces in one year,” Jean-Luc Herbeaux, its chief operating officer, says in a press release. Hovione is the sole producer of Captisol under a longstanding partnership with Ligand.
Hovione, the leader in spray drying and particle engineering, announced today an exclusive license agreement for a preclinical ophthalmology program, JX08, with Ji Xing Pharmaceuticals Limited (JIXING).
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform.